A Novel Osteogenic Activity of Suberoylanilide Hydroxamic Acid is Synergized by BMP-2

Area of Science:

• Epigenetics and Molecular Biology
• Bone Biology and Osteoporosis Research

Background:

• Histone deacetylase (HDAC) inhibitors are recognized for their anti-cancer properties.
• HDAC inhibition influences gene transcription and epigenetic regulation, impacting various biological processes.
• This study explores the osteogenic potential of suberoylanilide hydroxamic acid (SAHA; vorinostat), an HDAC inhibitor.

Purpose of the Study:

• To investigate the effects of SAHA on osteoblast differentiation and activity.
• To determine if SAHA influences the transcriptional activity and acetylation of runt-related transcription factor 2 (Runx2).
• To evaluate the efficacy of SAHA in an in vivo model of osteoporosis.

Main Methods:

• Osteoblast differentiation was assessed using a 6XOSE-Luc reporter assay to measure Runx2 activity and alkaline phosphatase (ALP) activity.
• Runx2 acetylation status was analyzed via immunoprecipitation assays.
• In vivo osteogenic activity was studied in a mouse model of receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoporosis.

Main Results:

• SAHA dose-dependently increased Runx2 transcriptional activity.
• SAHA enhanced bone morphogenetic protein-2 (BMP-2)-induced ALP activity but did not induce ALP activity alone.
• SAHA treatment increased Runx2 acetylation, suggesting stabilization of Runx2.
• SAHA effectively reversed osteoporotic bone loss induced by soluble RANKL.

Conclusions:

• SAHA exhibits osteogenic potential, particularly in a BMP-2-dependent manner.
• SAHA demonstrates efficacy in reversing osteoporosis-related bone loss in vivo.
• SAHA may be a viable therapeutic agent for osteoporosis, potentially at lower doses when combined with BMP-2.